{"title":"Unlocking the Potential of Exosomes: Transforming Wound Healing and Therapeutic Potential.","authors":"Shahjad, Nishat Fatma, Zeeshan Ali, Arun Kumar, Mohd Moonis, Phool Chandra","doi":"10.2174/0122115366384426250915095432","DOIUrl":"https://doi.org/10.2174/0122115366384426250915095432","url":null,"abstract":"<p><p>Difficulties in wound healing pose a considerable clinical problem and are a significant source of morbidity in the general population. Systemic disorders such as diabetes and venous insufficiency often result in chronic wounds and an impaired healing process. The healthcare cost of treating chronic wounds in the U.S. already exceeds 20 billion dollars per year and is expected to rise with an aging population and increasing incidence of diabetes. Recently, research and review articles have been used to understand the normal healing process and identify the reasons why certain wounds fail to heal, which should enable the development of more effective thera-peutic interventions. Animal models have provided valuable information; however, the healing process differs between humans and animals, and data obtained from in vitro studies can be chal-lenging to extrapolate to a clinical context. In conclusion, this study aims to summarize the current understanding of inflammation, epithelialization, and tissue repair processes, mainly through the use of data from in vitro and in vivo studies. Inflammation, re-epithelialization, granulation tissue development, and collagen remodeling are the fundamental steps in the healing process. As a result, any deviation from the normal sequence and time course of events may result in abnormal healing. Wound healing occurs to repair damaged, devitalized, or missing cells and tissues. In human beings, the result is the reestablishment of structural and functional integrity. This is a vital process that all living organisms undergo at some stage in their lives.</p>","PeriodicalId":38067,"journal":{"name":"MicroRNA (Shariqah, United Arab Emirates)","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145330405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Nanoparticle Carriers: A New Era of Precise CRISPR/Cas9 Gene Editing.","authors":"Bhawna Sharma, Iti Chauhan, Gaurav Kumar, Khushboo Bhardwaj, Raj Kumar Tiwari","doi":"10.2174/0122115366319848241022092805","DOIUrl":"10.2174/0122115366319848241022092805","url":null,"abstract":"<p><p>The revolutionary CRISPR/Cas9 gene editing technology holds immense potential for treating genetic diseases and tackling conditions like cancer. However, efficient delivery remains a significant challenge. This is where nanoparticles come into play, emerging as powerful allies in the realm of drug delivery. Nanoparticles can accommodate larger insertion sizes, enabling the incorporation of larger Cas9 enzymes and complex guide RNAs, thus opening up the possibility of editing previously inaccessible genetic regions. Their relatively straightforward and scalable production processes make them cost-effective options for wider applications. Notably, nanoparticles excel in vivo, demonstrating efficient tissue penetration and targeted delivery, which are crucial for maximizing therapeutic impact while minimizing side effects. This review aims to explore the potential of nanoparticle-based delivery systems for CRISPR/Cas9, highlighting their advantages and challenges in gene editing applications. The diverse range of nanoparticles further bolsters their potential. Polymeric nanoparticles, for instance, offer tunable properties for customization and controlled release of the CRISPR cargo. Lipid-based nanoparticles facilitate efficient cellular uptake and endosomal escape, ensuring the CRISPR components reach the target DNA. Even gold nanoparticles, known for their unique biocompatibility and photothermal properties, hold promise in light-activated editing strategies. Non-viral delivery systems, particularly those based on nanoparticles, stand out due to their inherent advantages. Collectively, the evidence paints a promising picture: nanoparticles are not merely passive carriers but active participants in the CRISPR/Cas9 delivery landscape. Their versatility, efficiency, and safety position them as key enablers of a future where gene editing can revolutionize drug development, offering personalized and targeted therapies for a wide range of diseases.</p>","PeriodicalId":38067,"journal":{"name":"MicroRNA (Shariqah, United Arab Emirates)","volume":" ","pages":"101-111"},"PeriodicalIF":1.6,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142559080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Identification of Hub Genes and Analysis of their Regulatory miRNAs in Patients with Thymoma Associated Myasthenia Gravis Based on TCGA Database.","authors":"Wei Zhou, Jia Hu, Jun Nie","doi":"10.2174/0122115366299210240823062457","DOIUrl":"10.2174/0122115366299210240823062457","url":null,"abstract":"<p><strong>Background: </strong>Myasthenia gravis is an autoimmune disease, and 30% of patients with thymoma often have myasthenia gravis. Patients with thymoma-associated MG (TAMG) have many different clinical presentations compared to non-MG thymoma (NMG), yet their gene expression differences remain unclear.</p><p><strong>Objective: </strong>In this study, we analyzed the Differentially Expressed Genes (DEGs) and analyzed their regulatory microRNAs (miRNAs) in TAMG, which will further clarify the possible pathogenesis of TAMG.</p><p><strong>Methods: </strong>DEGs were calculated using the RNA-sequencing data of TAMG and NMG downloaded from The Cancer Genome Atlas (TCGA) database. R software was then used to analyze the gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways of DEGs, while STRING was applied to build the protein-protein interaction (PPI) network and Cytoscape to identify and visualize the hub genes. Immune infiltration significances of hub genes were also explored by using the TIMER database and TCGA database. Upstream microRNAs (miRNAs) of the hub genes were predicted by online software.</p><p><strong>Results: </strong>We comparatively analyzed the gene expression differences between TAMG and NMG groups. A total of 977 DEGs were identified between the two groups (|log fold change (FC)| >2, adjusted P value <0.050), with 555 down-regulated genes and 422 up-regulated genes. Five top hub genes (CTNNB1, EGFR, SOX2, ERBB2, and EGF) were recognized in the PPI network. Analysis based on the TIMER and TCGA databases suggested that 5 hub genes were correlated with multiple immune cell infiltrations and immune checkpoint-related markers, such as PDCD1, CTLA-4, and CD274, in TAMG patients. Lastly, 5 miRNAs were identified to have the potential function of regulating the hub gene expression.</p><p><strong>Conclusion: </strong>Our study identified 5 hub genes (CTNNB1, EGFR, SOX2, ERBB2, and EGF) and their 5 regulatory miRNAs in TAMG, and the hub genes were correlated with multiple immune cell infiltrations and immune checkpoint-related markers. Our findings could help partially clarify the pathophysiology of TAMG, which could be new potential targets for subsequent clinical immunotherapy.</p>","PeriodicalId":38067,"journal":{"name":"MicroRNA (Shariqah, United Arab Emirates)","volume":" ","pages":"49-58"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12246741/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142082090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A Robust NSCLC Biomarker- miR-7-5p: Its <i>In-Silico</i> Validation and Potential SPR-Based Probe for Detection.","authors":"Chandrajeet Dhara, Anindita Dhara, Saumyatika Gantayat","doi":"10.2174/0122115366325862241031071038","DOIUrl":"10.2174/0122115366325862241031071038","url":null,"abstract":"<p><p>MicroRNA abundance as a particular biomarker for precisely identifying cancer metastases has emerged in recent years. The expression levels of miRNA are analyzed to get insights into cancer tissue detection and subtypes. Similar to other cancer types, the miRNA shows high levels of target mRNA dysregulation in association with non-small cell lung carcinoma (NSCLC). Among many promising cancer biomarkers for NSCLC, miR-7-5p has shown significant downregulation in the NSCLC tissues and targets proto-oncogenes like PAK2 and NOVA2. The expression levels of different proto-oncogenes targeting the miR-7-5p in NSCLC showed that the EGFR-mutated NSCLC has an experimental validation. The target validation of the miR-7-5p could be analyzed using SPR (Surface plasmon resonance) based sensors at a single nanoparticle level, such as Au nanocube, due to its high specificity and accountability. Despite being an accountable tool for cancer diagnosis, miRNA-based biomarkers sometimes cause poor diagnostic specificity and reproducibility due to their heterogenicity and immunogenicity in cancer detection. To overcome these shortcomings, the biomarkers need to be validated according to recent clinical studies.</p>","PeriodicalId":38067,"journal":{"name":"MicroRNA (Shariqah, United Arab Emirates)","volume":" ","pages":"112-123"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142928473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Identification of Key miRNAs in Endometriosis.","authors":"Francesca Blandino, Saviana Antonella Barbati, Luca Forlani, Giulia Coppola, Noemi Meschino, Ilde Cecchinelli, Antonietta Cosco Mazzuca, Valentina Veltri, Riccardo Giannico, Graziella Calugi","doi":"10.2174/0122115366333556241014115206","DOIUrl":"10.2174/0122115366333556241014115206","url":null,"abstract":"<p><strong>Introduction: </strong>Endometriosis, a prevalent gynecological disorder characterized by the presence of endometrial-like tissue outside the uterus, poses significant challenges in diagnosis and management due to its unclear pathogenesis and lack of specific biomarkers.</p><p><strong>Objective: </strong>This study investigates the potential use of microRNAs (miRNAs) as key markers in endometriosis by studying two cohorts of patients (14 patients diagnosed with endometriosis and 15 patients with gynecological benign lesions, different from endometriosis).</p><p><strong>Methods: </strong>MicroRNA sequencing analysis was tested within data management by a custom pipeline designed by Eurofins Genoma Group.</p><p><strong>Results: </strong>We identified a specific miRNA expression profile associated with endometriosis to feature specific disease molecular clusters to further elucidate the underlying mechanisms driving endometriosis pathogenesis. Data from the present study suggest a specific miRNA scar for endometriosis compared to other gynecological diseases to develop screening tools in early diagnosis and to ameliorate the management of the disease itself.</p><p><strong>Conclusion: </strong>This study lays the foundation for the identification of key miRNAs involved in the disease pathogenesis to unveil the molecular signatures in the complex scenario of endometriosis. Further validation and exploration of these findings are needed to develop tools to improve molecular diagnosis and to create a machine-learning prediction algorithm in the future.</p>","PeriodicalId":38067,"journal":{"name":"MicroRNA (Shariqah, United Arab Emirates)","volume":" ","pages":"170-175"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142548048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Evaluation of Salivary and Serum micro RNA 146a, 200c and its Target Gene PTEN in Chronic Periodontitis Patients and their Response to Non-Surgical Periodontal Therapy.","authors":"Jammula Surya Prasanna, Kunnel Apoorva","doi":"10.2174/0122115366319964241020165218","DOIUrl":"10.2174/0122115366319964241020165218","url":null,"abstract":"<p><strong>Background: </strong>Periodontitis destroys the tooth's supporting structures and attachment apparatus. Local or systemic factors can cause it. Traditionally, diagnosis is based on clinical parameters that may not consistently reflect an accurate confirmation. Biochemical and genetic analyses can provide deeper insights. MicroRNAs (miRNAs) regulate the immune and inflammatory response to microbial pathogens. Detecting and evaluating miRNAs can be an important diagnostic parameter. This study aimed to assess the expression of miRNA 146a,200c, and its target gene PTEN to non-surgical periodontal therapy in serum and saliva.</p><p><strong>Materials and methods: </strong>This interventional comparative study was conducted on 120 patients of both genders, ages between 35 and 55. Non-surgical periodontal therapy (NSPT) scaling and root planing were performed on all subjects, and their saliva and serum samples were collected before and after 8 weeks of NSPT. Quantitative rt-PCR (reverse transcriptase Polymerase Chain Reaction) analysis was conducted on all samples. The statistical analysis was done using SPSS version 22, and comparisons were made using paired t-tests, independent t-tests, and Pearson's correlation coefficient. The statistical significance level was set at a 'P' value of less than 0.05.</p><p><strong>Results: </strong>It has been observed that there was a significant difference of miRNA in both serum and saliva samples 146a,200c, and the PTEN gene expression, from the beginning to 8 weeks. Significant variation was not observed when comparing the levels between serum and saliva.</p><p><strong>Conclusion: </strong>miRNA 146A, 200c, and PTEN genes are interrelated with periodontitis. We can consider them as future biomarkers of periodontal diseases.</p>","PeriodicalId":38067,"journal":{"name":"MicroRNA (Shariqah, United Arab Emirates)","volume":" ","pages":"136-146"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12645113/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142956391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"micro-RNA 451-a as a Circulating Biomarker for Neuroblastoma.","authors":"Aditya Kumar Gupta, Aijaz Ahmad, Disha Kakker, Jagdish Prasad Meena, Ravi Kumar Majhi, Ambreen Jan, Rachna Seth, Venkatesawaran Iyer, Saumyaranjan Mallick","doi":"10.2174/0122115366361597250108075627","DOIUrl":"10.2174/0122115366361597250108075627","url":null,"abstract":"<p><strong>Introduction: </strong>Micro ribonucleic acids (miRNAs) are small non-coding RNAs that modulate the expression of various genes. They have an important role in cancer pathogenesis. Differential expression of multiple miRNAs have been used as potential diagnostic and prognostic markers.</p><p><strong>Methods: </strong>Various miRNAs have lately been employed as diagnostic and therapeutic targets in different cancers. This prospective study included untreated pediatric neuroblastoma (NB) patients. In the discovery phase, global miRNA profiling was done using next-generation sequencing (NGS) on biopsy tissue samples of NB patients. In this phase, the top expressing miRNAs were identified and chosen for further validation as circulating miRNA in blood samples of a different set of NB patients by real-time polymerase chain reaction (PCR).</p><p><strong>Results: </strong>Based on the read counts on the global miRNA profiling in the discovery phase, we found that the miRNA that consistently had high reads across the majority of the NB samples were miRNA 451-a, 19b-3p, 106b-5p, and 21-5p. Of these, we selected miRNA 451-a and 19-b for the validation phase of the study as they had consistent overexpression. In the validation phase, the expression of the circulating miRNA 451-a in the blood was found to be higher. The average value for the relative fold (RF) expression for miRNA 451-a was 1.52.</p><p><strong>Conclusion: </strong>miRNA 451-a is overexpressed both in the cancer tissue and the blood of NB patients. It can serve as a potential diagnostic marker. Further studies can elucidate its role in the pathogenesis of NB and it could have utility as a therapeutic target.</p>","PeriodicalId":38067,"journal":{"name":"MicroRNA (Shariqah, United Arab Emirates)","volume":" ","pages":"226-233"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142984992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"miRVim: Three-dimensional miRNA Structure Database.","authors":"Vishal Kumar Sahu, Ankita Subhadarsani Parida, Amit Ranjan, Harishkumar Madhyastha, Soumya Basu","doi":"10.2174/0122115366307988240809045125","DOIUrl":"10.2174/0122115366307988240809045125","url":null,"abstract":"<p><strong>Introduction: </strong>MicroRNAs (miRNAs), a distinct category of non-coding RNAs, exert multifaceted regulatory functions in a variety of organisms, including humans, animals, and plants. The inventory of identified miRNAs stands at approximately 60,000 among all species and 1,926 in Homo sapiens manifests miRNA expression. Their theranostic role has been explored by researchers over the last few decades, positioning them as prominent therapeutic targets as our understanding of RNA targeting advances. However, limited availability of experimentally determined miRNA structures has constrained drug discovery efforts relying on virtual screening or computational methods, including machine learning and artificial intelligence.</p><p><strong>Methods: </strong>To address this lacuna, miRVim has been developed, providing a repository of human miRNA structures derived from both two-dimensional (MXFold2, CentroidFold, and RNAFold) and three-dimensional (RNAComposer and 3dRNA) structure prediction algorithms, in addition to experimentally available structures from the RCSB PDB repository.</p><p><strong>Results: </strong>miRVim contains 13,971 predicted secondary structures and 17,045 predicted three-dimensional structures filling the gap of unavailability of miRNA structure data bank. This database aims to facilitate computational data analysis for drug discovery, opening new avenues for advancing technologies such as machine learning-based predictions in the field of RNA biology.</p><p><strong>Conclusion: </strong>The publicly accessible structures provided by miRVim, available at https://mirna.in/miRVim, offer a valuable resource for the research community, advancing the field of miRNA-related computational analysis and drug discovery.</p>","PeriodicalId":38067,"journal":{"name":"MicroRNA (Shariqah, United Arab Emirates)","volume":" ","pages":"59-72"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142019051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A Potential Regulatory Network of Selected Human Erythrocytic miRNAs with <i>Plasmodium falciparum</i> 3D7 mRNAs: A Computational Analysis.","authors":"Urja Joshi, Harsha Motwani, Dhara Jani, Linz-Buoy George, Hyacinth Highland","doi":"10.2174/0122115366321119250123113447","DOIUrl":"10.2174/0122115366321119250123113447","url":null,"abstract":"<p><strong>Background: </strong>miRNAs are small non-coding conserved RNA molecules (18-24 nts) that act as crucial gene regulators via post-transcriptional/translational modifications through interacting with the respective mRNAs during various pathophysiological conditions. Recent research has suggested that non-coding RNAs, particularly miRNAs, can be passed from one species to another to regulate gene expression. Since miRNA-mediated gene regulation has not yet been found in Plasmodia, it is hypothesized that erythrocytic miRNAs from Plasmodium falciparum (P. falciparum) could potentially migrate from the cytoplasm to the parasitophorous vacuole developed intracellularly by the parasite to regulate its transcriptome.</p><p><strong>Objective: </strong>The objective of this study is to investigate the role of trans-kingdom interactions in host-parasite dynamics and their implications for malaria infection.</p><p><strong>Methods: </strong>Using the trans-kingdom target gene prediction tool, psRNA target server, a total of 15 human erythrocytic miRNAs from 12 distinct families were selected and obtained from miRBase to find potential P. falciparum candidate genes. This study utilized ShinyGO (version 0.80) for gene enrichment analysis with statistical analysis of the selected features. The PPI-network analysis was performed using the Maximal Clique Centrality (MCC) approach, along with the CytoHubba plugin for identifying hub nodes. The PPI network was visualized using Cytoscape version 3.7.</p><p><strong>Results: </strong>A total of 145 target genes of Pf3D7 were predicted, with the following genes repeatedly targeted: conserved Plasmodium proteins, conserved Plasmodium membrane proteins, PfEMP1, rifin, RAD54, E3 ubiquitin-protein ligase, and transcription factors related genes. Outputs of ShinyGO included enriched GO pathways of 62 uniquely identified Pf3D7 genes with detailed descriptions and visualized networks. For overlapping relationships, a hierarchical clustering tree of enriched gene sets was carried out, along with a genome plot for representing the chromosomal locations of these genes. According to their coding-noncoding distribution chart, most of these genes were found to be members of the coding gene family. Additionally, PPI-network analysis reported the top 10 hub nodes: PFE0400w, MAL13P1.380, MAL7P1.167, PFD0900w, PF11_0243, PFE0440w, PFE1120w, MAL13P1.315, PF08_0126, and MAL8P1.23. Three KEGG pathway diagrams of pfa 05144 for Malaria, pfa 03440 for homologous recombination, and pfa 00750 for vitamin B6 metabolism with identified Pf3D7 genes were drawn and highlighted in red.</p><p><strong>Conclusion: </strong>The important target genes of Plasmodium falciparum 3D7 were identified by carrying out a trans-kingdom investigation, thus offering preliminary insights into the potential of erythrocytic miRNAs-mediated trans-kingdom regulation.</p>","PeriodicalId":38067,"journal":{"name":"MicroRNA (Shariqah, United Arab Emirates)","volume":" ","pages":"147-169"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143415616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Eleni Antoniou, Evangelos Oikonomou, Panagiotis Theofilis, Vaia Lambadiari, Eva Kassi, Christos Chasikidis, Konstantinos Zisimos, Konstantinos Andreou, Vasiliki Kalogera, Ourania Katsarou, Elena Foti, Eva Kleopa, Athanasia Striki, Gerasimos Siasos
{"title":"MicroRNAs in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review of Clinical Studies.","authors":"Eleni Antoniou, Evangelos Oikonomou, Panagiotis Theofilis, Vaia Lambadiari, Eva Kassi, Christos Chasikidis, Konstantinos Zisimos, Konstantinos Andreou, Vasiliki Kalogera, Ourania Katsarou, Elena Foti, Eva Kleopa, Athanasia Striki, Gerasimos Siasos","doi":"10.2174/0122115366359521250122115511","DOIUrl":"10.2174/0122115366359521250122115511","url":null,"abstract":"<p><strong>Introduction: </strong>Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is a major contributor to global morbidity and mortality. As diagnostic tools for MASLD remain limited, microRNAs (miRs) have garnered attention as promising biomarkers due to their roles in regulating metabolic pathways and reflecting disease states.</p><p><strong>Methods: </strong>This systematic review of clinical studies explores the association between miRNAs and the spectrum of MASLD-related pathologies, including steatosis, fibrosis, and Hepatocellular Carcinoma (HCC). A comprehensive literature search was conducted using PRISMA guidelines, resulting in 44 peer-reviewed studies being included. The review identifies several key miRs, such as miR-122, miR-34a, and miR-193-5p, which are linked to lipid metabolism, insulin resistance, and MASLD severity.</p><p><strong>Results: </strong>Additionally, miR-214 and miR-193-5p are highlighted as potential biomarkers for fibrosis, while miR-21 and miR-34a are implicated in the progression of HCC. These miRs were found in various tissues, including serum, liver, visceral adipose tissue, and ascitic fluid, demonstrating their utility as diagnostic and prognostic tools across the MASLD spectrum.</p><p><strong>Conclusion: </strong>While miR panels are being developed for clinical assessment, further research is required to confirm their roles in diagnosis and treatment, as well as their integration into routine clinical practice.</p>","PeriodicalId":38067,"journal":{"name":"MicroRNA (Shariqah, United Arab Emirates)","volume":" ","pages":"214-225"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143400271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}